Teva (TEVA) Pharmaceuticals Industries is responding to the European Decision following its investigation into the company’s practices regarding COPAXONE — the standard-of-care treatment for multiple sclerosis – and announcing its intention to appeal the judgement and fine imposed. The company is deeply disappointed by this decision and has been cooperating extensively with the EC since 2019. Teva disagrees with the Commission’s legal theories which are legally untested and, Teva believes, not supported by the facts. The company will vigorously defend its position on appeal and is well prepared financially to mount a defense.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva price target raised to $25 from $22 at Barclays
- Teva call volume above normal and directionally bullish
- Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI
- Biotech Alert: Searches spiking for these stocks today
- Uber said to consider Expedia bid, CSX posts Q3 miss: Morning Buzz